Research Articles | Page 17 | Aplastic Anemia & MDS International Foundation Return to top.
  1. Articles
  2. Research Articles

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials Oct 2016 Leukemia myelodysplastic syndromes (MDS)
Distinct iron architecture in SF3B1 mutant myelodysplastic syndromes patients is linked to an SLC25A37 splice variant with a retained intron May 2014 Leukemia myelodysplastic syndromes (MDS)
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides Oct 2015 Leukemia
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias Feb 2013 Leukemia myelodysplastic syndromes (MDS)
Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Feb 2017 Leukemia myelodysplastic syndromes (MDS)
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes Mar 2015 Leukemia myelodysplastic syndromes (MDS)
Therapy-related Myelodysplastic Syndromes Deserve Specific Diagnostic Sub-Classification and Risk-Stratification-An Approach to Classification of Patients With t-MDS Jun 2020 Leukemia myelodysplastic syndromes (MDS)
Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Jan 2021 Leukemia myelodysplastic syndromes (MDS)
Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria Jan 2021 Leukemia paroxysmal nocturnal hemoglobinuria (PNH)
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes Oct 2015 Leukemia myelodysplastic syndromes (MDS)
Share with addtoany.com.